Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

    Diabetes, Obesity and Metabolism Date published:

  • Reassurance for parents with children bornvia assisted reproductive technology or too soon to tell?

    European Heart Journal Date published:

  • The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme

    Diabetes, Obesity and Metabolism Date published:

  • Contemporary Chest Pain Evaluation: The Australian Case for Cardiac CT

    Heart, Lung and Circulation Date published:

  • Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Management of chronic breathlessness in primary care: what do GPs, non-GP specialists, and allied health professionals think?

    Australian Journal of Primary Health Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial

    Date published:

  • Investigating opportunities to prevent Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: the DIVINE-NSW study

    Unknown Date published:

  • Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension - the SaltSwitch Online Grocery Shopping randomized trial

    American Heart Journal Date published:

  • Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

    Heart Failure Clinics Date published:

  • Sex disaggregated analysis of risk factors for adverse outcomes in hypertrophic cardiomyopathy

    European Heart Journal Date published:

  • Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Cardiovascular Diabetology Date published:

  • Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Diabetes Care Date published:

  • Multidisciplinary perspectives on the role of primary care in managing chronic breathlessness

    01.03 - General practice and primary care Date published:

  • Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

    Journal of the American Heart Association Date published: